Torin 1

Catalog No.S2827

Molecular Weight(MW): 607.62

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Cited by 98 Publications

Cell, 2019, 177(4):896-909

PubMed: 31030999 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Cell Metab, 2018, 28(3):369-382

PubMed: 30043754 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4741

PubMed: 31628323 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1693

PubMed: 30979895 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5681

PubMed: 31831743 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1703353

PubMed: 31847700 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1628536

PubMed: 31203721 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1911393116

PubMed: 31732667 ( click the link to review the publication )

Cell Rep, 2019, 29(3):589-602

PubMed: 31618629 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Cell Mol Immunol, 2019, 10.1038/s41423-019-0281-6

PubMed: 31467416 ( click the link to review the publication )

Oncogene, 2019, 38(10):1639-1650

PubMed: 30337688 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )
EBioMedicine, 2019, 40:151-162

PubMed: 30711516 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):399

PubMed: 31113939 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Biochem Pharmacol, 2019, 162:191-201

PubMed: 30471247 ( click the link to review the publication )

J Biol Chem, 2019, 294(10):3760-3771

PubMed: 30617181 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(4):909-915

PubMed: 31563324 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4831

PubMed: 30446646 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5426

PubMed: 30575721 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2819

PubMed: 30026551 ( click the link to review the publication )

J Pathol, 2018, 245(2):235-248

PubMed: 29570219 ( click the link to review the publication )

PLoS Genet, 2018, 14(5):e1007369

PubMed: 29750810 ( click the link to review the publication )

Development, 2018, 145(18)

PubMed: 30126904 ( click the link to review the publication )

Lung Cancer, 2018, 120:34-45

PubMed: 29748013 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Exp Cell Res, 2018, 363(1):84-94

PubMed: 29289595 ( click the link to review the publication )

Braz J Med Biol Res, 2018, 51(6):e7080

PubMed: 29694502 ( click the link to review the publication )

Cell Res, 2017, 27(2):184-201

PubMed: 27934868 ( click the link to review the publication )

Mol Cell, 2017, 67(6):907-921

PubMed: 28844862 ( click the link to review the publication )

Mol Cell, 2017, 65(6):1029-1043

PubMed: 28306502 ( click the link to review the publication )

Nat Commun, 2017, 8:15045

PubMed: 28429794 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Autophagy, 2017, 13(4):686-702

PubMed: 28121484 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

PLoS Pathog, 2017, 13(3):e1006249

PubMed: 28249048 ( click the link to review the publication )
Sci Rep, 2017, 7(1):13832

PubMed: 29062139 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14544-14555

PubMed: 28684424 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(31):6625-6637

PubMed: 28697598 ( click the link to review the publication )

Radiat Res, 2017, 187(3):382-396

PubMed: 28327001 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93688-93703

PubMed: 29212182 ( click the link to review the publication )

Oncotarget, 2017, 8(52):89527-89538

PubMed: 29163768 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109848-109856

PubMed: 29312653 ( click the link to review the publication )

Oncotarget, 2017, 8(27):44550-44566

PubMed: 28562352 ( click the link to review the publication )

Protein Cell, 2016, 7(12):878-887

PubMed: 27909983 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(5):580-90

PubMed: 27025692 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(5):1428-37

PubMed: 26938669 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(2):321-33

PubMed: 26582390 ( click the link to review the publication )

J Biol Chem, 2016, 291(33):17467-77

PubMed: 27339899 ( click the link to review the publication )

J Cell Physiol, 2016, 10.1002/jcp.25456

PubMed: 27301841 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

BMC Musculoskelet Disord, 2016, 17:150

PubMed: 27052304 ( click the link to review the publication )

Oncotarget, 2016, 7(34):55690-55703

PubMed: 27494886 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6559-73

PubMed: 26237138 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:15

PubMed: 25849580 ( click the link to review the publication )
J Cell Physiol, 2015, 230(5):1064-74

PubMed: 25283437 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Virol, 2015, 89(1):626-42

PubMed: 25339775 ( click the link to review the publication )

Sci Rep, 2015, 5:13891

PubMed: 26403635 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M114.621706

PubMed: 25878248 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

Cell Signal, 2015, 27(8):1557-68

PubMed: 25936523 ( click the link to review the publication )

BMC Cancer, 2015, 15:855

PubMed: 26542945 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0135614

PubMed: 26267903 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23238-48

PubMed: 26177051 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1214

PubMed: 24810050 ( click the link to review the publication )

Am J Pathol, 2014, 184(1):214-29

PubMed: 24215913 ( click the link to review the publication )

J Biol Chem, 2014, 289(43):29739-49

PubMed: 25164809 ( click the link to review the publication )

J Biol Chem, 2014, 289(25):17830-42

PubMed: 24798333 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.05.047

PubMed: 24858682 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12715-27

PubMed: 25587030 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6816-31

PubMed: 25149175 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

Trends Microbiol, 2013, 21(6):286-95

PubMed: 23608036 ( click the link to review the publication )

Genes Dev, 2013, 27(10):1115-31

PubMed: 23699409 ( click the link to review the publication )
PLoS One, 2013, 8(11):e80070

PubMed: 24244612 ( click the link to review the publication )

EMBO Mol Med, 2011, 3(4):189-200

PubMed: 21412983 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	NEL2Sm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHpTWM2OD1yLkCwNFMxPiEQvF2=	MXLTRW5ITVJ?
OCUB-M	NGKyO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rPTGlEPTB;MD6wNFE6PCEQvF2=	MV;TRW5ITVJ?
DOHH-2	NV7SPYppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LiUmlEPTB;MD6wNFIzPSEQvF2=	MkPLV2FPT0WU
NOS-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{[zZmlEPTB;MD6wNFI1OiEQvF2=	M{e3N3NCVkeHUh?=
L-363	M{nnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\zPGtKSzVyPUCuNFAzQDRizszN	MnTtV2FPT0WU
RL95-2	M3fMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\QcGlEPTB;MD6wNFMzKM7:TR?=	MYDTRW5ITVJ?
BL-70	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTlTXhSUUN3ME2wMlAxOzN5IN88US=>	Mm\2V2FPT0WU
TGBC1TKB	NGPEUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLufWZQUUN3ME2wMlAxOzd7IN88US=>	Ml;mV2FPT0WU
697	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3u4PWlEPTB;MD6wNFY{PCEQvF2=	NYLsfpFvW0GQR1XS
RPMI-8226	M2TWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnq1TWM2OD1yLkCwOlUyKM7:TR?=	NXLRdWdJW0GQR1XS
BL-41	NEfISFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDsfGJKSzVyPUCuNFA3QTZizszN	NGi4PGdUSU6JRWK=
MRK-nu-1	NUPudJJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfuTWM2OD1yLkCwO\|A4KM7:TR?=	M1LHSXNCVkeHUh?=
EW-1	NIK5TXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17MPGlEPTB;MD6wNFc1QSEQvF2=	Ml3XV2FPT0WU
EVSA-T	NFrGeo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jtSmlEPTB;MD6wNFg6OiEQvF2=	M{jYXnNCVkeHUh?=
HUTU-80	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LsR2lEPTB;MD6wNFkzQSEQvF2=	M4\zeXNCVkeHUh?=
VA-ES-BJ	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfOTWM2OD1yLkCwPVg1KM7:TR?=	NVq2TJBzW0GQR1XS
GCIY	NVnxNmFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMEGwNFch\|ryP	M{PMU3NCVkeHUh?=
ES6	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7NTWM2OD1yLkCxNFg{KM7:TR?=	NHezdmJUSU6JRWK=
NALM-6	M13lWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXnSohKSzVyPUCuNFEyODJizszN	MVTTRW5ITVJ?
LB996-RCC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7vNoszUUN3ME2wMlAyOTN5IN88US=>	NGDWSFhUSU6JRWK=
EW-16	MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jCZmlEPTB;MD6wNVE6OiEQvF2=	MlLzV2FPT0WU
KALS-1	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTSd5RoUUN3ME2wMlAyOTl6IN88US=>	NH;r[HlUSU6JRWK=
OPM-2	M3q0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\LVVdKSzVyPUCuNFEzQSEQvF2=	MV\TRW5ITVJ?
KU812	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\BbWlEPTB;MD6wNVI6PiEQvF2=	MW\TRW5ITVJ?
A4-Fuk	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVz5bWN2UUN3ME2wMlAyOzF7IN88US=>	NXfxT21QW0GQR1XS
KGN	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHtdppKSzVyPUCuNFE{PTlizszN	NH;Wc5VUSU6JRWK=
KS-1	NUX4UWtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnicINTUUN3ME2wMlAyOzl{IN88US=>	NVG5c2h2W0GQR1XS
no-11	M3XtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULEemlvUUN3ME2wMlAyOzl3IN88US=>	Ml6zV2FPT0WU
PSN1	NUHQfJZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEG0NFkh\|ryP	NEj3[pZUSU6JRWK=
SK-LMS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnZd\|R3UUN3ME2wMlAyPDF\|IN88US=>	NHviOWZUSU6JRWK=
LS-411N	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPRTWM2OD1yLkCxOFM6KM7:TR?=	NGLNUHlUSU6JRWK=
HT-144	NGjBc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMEG0OVEh\|ryP	NGPIRVVUSU6JRWK=
ACN	M1P4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPqR2ZoUUN3ME2wMlAyPSEQvF2=	MlvQV2FPT0WU
RKO	NF;CRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnziTWM2OD1yLkCxOVM{KM7:TR?=	MkHRV2FPT0WU
CMK	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMEG1OFMh\|ryP	NWfWTVdQW0GQR1XS
GB-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HaU2lEPTB;MD6wNVU2OyEQvF2=	NUntOHE3W0GQR1XS
KE-37	MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3ENo9wUUN3ME2wMlAyPTd\|IN88US=>	MX3TRW5ITVJ?
no-10	MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwMEG1PFQh\|ryP	NYe2N4lnW0GQR1XS
MOLT-16	MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMEG2NlIh\|ryP	MkK1V2FPT0WU
HEL	NVHQbWZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEG2OEDPxE1?	MXzTRW5ITVJ?
NCI-H1355	NEfMUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLHVI1KSzVyPUCuNFE3PDZizszN	M4T1UnNCVkeHUh?=
IST-MEL1	M3:wcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7pZWJKSzVyPUCuNFE4PzRizszN	MXjTRW5ITVJ?
MHH-PREB-1	M{DDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDyN5hKSzVyPUCuNFE5OThizszN	M3PYN3NCVkeHUh?=
ES8	M3Plemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfSem5KSzVyPUCuNFE5PDRizszN	NW\Se3J4W0GQR1XS
LC-2-ad	NXTTOlJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjsO25ZUUN3ME2wMlAzOTN5IN88US=>	MW\TRW5ITVJ?
LAMA-84	NFziV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LRN2lEPTB;MD6wNlE3PyEQvF2=	M4Pne3NCVkeHUh?=
BV-173	MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMEKyNFMh\|ryP	MV;TRW5ITVJ?
SW872	M2K0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIf0VlBKSzVyPUCuNFIzPDdizszN	NUfFRmRmW0GQR1XS
SK-UT-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f1SWlEPTB;MD6wNlI3OSEQvF2=	NWrHfXRTW0GQR1XS
OS-RC-2	NHzUXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnMR5AxUUN3ME2wMlAzOzJ\|IN88US=>	NGDoXZBUSU6JRWK=
NCI-H747	NHG5UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXiwZlR5UUN3ME2wMlAzOzNizszN	NIW0RWxUSU6JRWK=
MZ2-MEL	M{DzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PBUWlEPTB;MD6wNlM{PyEQvF2=	NFvLcnBUSU6JRWK=
TE-11	NHGxVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHSZVk3UUN3ME2wMlAzOzd{IN88US=>	NF[4NmFUSU6JRWK=
KURAMOCHI	NULaU4ptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\FTWM2OD1yLkCyOFE1KM7:TR?=	NECwWpNUSU6JRWK=
HD-MY-Z	NYnmU4VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn25TWM2OD1yLkCyOFI3KM7:TR?=	NGnndppUSU6JRWK=
GI-1	NIC3R\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7pS3N{UUN3ME2wMlAzPDZ7IN88US=>	NX7FS2dnW0GQR1XS
LB1047-RCC	NFPiN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHZfmZNUUN3ME2wMlAzPDh6IN88US=>	NUDOVXdbW0GQR1XS
TE-12	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUD3XnZQUUN3ME2wMlAzPTVizszN	M4Pn[nNCVkeHUh?=
MZ7-mel	NF\5SZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzUXYxKSzVyPUCuNFI3ODlizszN	NXjwXpZMW0GQR1XS
MMAC-SF	NV7XSI5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3n3OWlEPTB;MD6wNlY{OyEQvF2=	NV6xS\|BpW0GQR1XS
A101D	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoX1TWM2OD1yLkCyOlUh\|ryP	MkDhV2FPT0WU
GR-ST	NGjUXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTzTWM2OD1yLkCyOlU2KM7:TR?=	NES1UGJUSU6JRWK=
MC116	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEK2PEDPxE1?	NFjpfY5USU6JRWK=
Ramos-2G6-4C10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4X5dWlEPTB;MD6wNlc2KM7:TR?=	NVXpWHB7W0GQR1XS
ATN-1	NGLSR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvyTWM2OD1yLkCyO\|g6KM7:TR?=	MWPTRW5ITVJ?
MFH-ino	NVP5S\|F7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV64dVR5UUN3ME2wMlAzQDF{IN88US=>	NF3LOm9USU6JRWK=
DEL	NXLXeHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMEK4NVUh\|ryP	NYPUPWtFW0GQR1XS
OCI-AML2	MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37KemlEPTB;MD6wNlg4OSEQvF2=	MVXTRW5ITVJ?
LXF-289	MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrxTWM2OD1yLkCyPFczKM7:TR?=	MWPTRW5ITVJ?
IA-LM	NEXTbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnaTWM2OD1yLkCyPVE4KM7:TR?=	NUHHTYJXW0GQR1XS
EoL-1-cell	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPpeGJqUUN3ME2wMlAzQTl4IN88US=>	NVjMc2tWW0GQR1XS
OVCAR-4	M3f4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TxUGlEPTB;MD6wN\|A6PCEQvF2=	NFHGTW9USU6JRWK=
ES1	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7t[VZKSzVyPUCuNFMxQTdizszN	M{HWUXNCVkeHUh?=
CESS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEOwPVkh\|ryP	MWHTRW5ITVJ?
GAK	NUXPVJh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn74TWM2OD1yLkCzNVg3KM7:TR?=	NWTpRpg3W0GQR1XS
NTERA-S-cl-D1	NVz0TYhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMEOyNlYh\|ryP	Ml;KV2FPT0WU
TE-10	M{XyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3myVWlEPTB;MD6wN\|MyOSEQvF2=	NV3kVWNvW0GQR1XS
CCRF-CEM	M3\mS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHlTWM2OD1yLkCzN\|cyKM7:TR?=	MknjV2FPT0WU
NMC-G1	MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknyTWM2OD1yLkCzOFQ5KM7:TR?=	MVPTRW5ITVJ?
HOP-62	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULS[pRWUUN3ME2wMlA{PTV4IN88US=>	NFHqToJUSU6JRWK=
SH-4	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvaOnFKSzVyPUCuNFM2QDJizszN	NFvZfHBUSU6JRWK=
NCI-H1648	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzhWnVRUUN3ME2wMlA{PjJ{IN88US=>	NIfQclBUSU6JRWK=
EB-3	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHT3SFhKSzVyPUCuNFM3PDNizszN	NWPrU4NxW0GQR1XS
BB65-RCC	NYfTPW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUG2XWpLUUN3ME2wMlA{PjlzIN88US=>	MWDTRW5ITVJ?
BE-13	NIW2elhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XTUWlEPTB;MD6wN\|c2QSEQvF2=	M3vuVXNCVkeHUh?=
CP67-MEL	NV3CZ5dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nLeWlEPTB;MD6wN\|c2QSEQvF2=	Mn3yV2FPT0WU
SW954	NFm5d3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;6U4RrUUN3ME2wMlA{PzlizszN	NHPWV3VUSU6JRWK=
TE-5	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\hWY9KSzVyPUCuNFM5PTRizszN	MYjTRW5ITVJ?
HCE-4	NIDLTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMEO4OVUh\|ryP	NFPrPG5USU6JRWK=
LC-1F	M3[wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXPO3NKSzVyPUCuNFM6QDlizszN	MY\TRW5ITVJ?
TK10	NIftRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrlZlNKUUN3ME2wMlA1ODF7IN88US=>	NGDCVpRUSU6JRWK=
SJSA-1	NHixRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:xOWlEPTB;MD6wOFE5QCEQvF2=	NFrSWIxUSU6JRWK=
Daudi	M122d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrEPINKSzVyPUCuNFQzOjVizszN	MXLTRW5ITVJ?
SW982	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\2cHh3UUN3ME2wMlA1OjR4IN88US=>	Ml[yV2FPT0WU
SF126	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\hTWM2OD1yLkC0N\|YyKM7:TR?=	MnTwV2FPT0WU
TE-15	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[0b3prUUN3ME2wMlA1PDN3IN88US=>	M{\ifHNCVkeHUh?=
COLO-684	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HBT2lEPTB;MD6wOFU3OSEQvF2=	M4HmV3NCVkeHUh?=
8-MG-BA	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMES2Nlkh\|ryP	NET4VmdUSU6JRWK=
NB13	NWjMVogzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMES3O\|Yh\|ryP	MnzxV2FPT0WU
HCC1599	NWXiN4ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojSTWM2OD1yLkC0PFc6KM7:TR?=	M2HiNnNCVkeHUh?=
SK-PN-DW	NIL6[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvXTHBKSzVyPUCuNFQ6PDlizszN	NFLqS5BUSU6JRWK=
ALL-PO	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LEfmlEPTB;MD6wOFk2PiEQvF2=	NYjuRmRzW0GQR1XS
NB6	NIDMRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMEWyO\|Eh\|ryP	MmjTV2FPT0WU
IST-SL2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3wTWM2OD1yLkC1N\|YzKM7:TR?=	M3HYNnNCVkeHUh?=
BB30-HNC	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMEW3N{DPxE1?	NFK2c2ZUSU6JRWK=
SW962	M2riTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;rN4VOUUN3ME2wMlA2PzZ\|IN88US=>	MUTTRW5ITVJ?
TGBC24TKB	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{W0XmlEPTB;MD6wOVc6QSEQvF2=	NHjGW5dUSU6JRWK=
KINGS-1	Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\zUWlEPTB;MD6wOVgxOyEQvF2=	NFv3fFBUSU6JRWK=
HC-1	NWC0SpBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\GSWFKSzVyPUCuNFU5OjdizszN	NUjtTmtGW0GQR1XS
RS4-11	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMEW5N\|gh\|ryP	MoLFV2FPT0WU
LS-123	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4W2ZmlEPTB;MD6wOVk1OiEQvF2=	NFLPRZBUSU6JRWK=
A3-KAW	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwME[yNlUh\|ryP	NGHUTppUSU6JRWK=
SNB75	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LHemlEPTB;MD6wOlM1OSEQvF2=	MW\TRW5ITVJ?
SR	M{XCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;zbGlEPTB;MD6wOlM4PCEQvF2=	M33aenNCVkeHUh?=
LOUCY	M1fVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXuyRXRYUUN3ME2wMlA3Ozl2IN88US=>	Mon6V2FPT0WU
K5	M2jWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwME[0NFMh\|ryP	Moq1V2FPT0WU
Becker	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HlfWlEPTB;MD6wOlQzKM7:TR?=	MmixV2FPT0WU
CTV-1	M1\idGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjPR5BlUUN3ME2wMlA3PTR6IN88US=>	NGH5V2RUSU6JRWK=
KLE	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\6TWM2OD1yLkC2OVg1KM7:TR?=	MULTRW5ITVJ?
MZ1-PC	NXr5SnZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rsUmlEPTB;MD6wOlU6QCEQvF2=	MlzFV2FPT0WU
MOLT-4	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jROWlEPTB;MD6wOlYxPSEQvF2=	MUjTRW5ITVJ?
MLMA	NEKzT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwME[3PEDPxE1?	M2PCcHNCVkeHUh?=
A388	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ETWM2OD1yLkC2PFk{KM7:TR?=	M2\SNnNCVkeHUh?=
MV-4-11	MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwME[5PVUh\|ryP	M2XlTHNCVkeHUh?=
DSH1	MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPMPXZxUUN3ME2wMlA4OTd\|IN88US=>	MkTLV2FPT0WU
MONO-MAC-6	M3H3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnwTWM2OD1yLkC3NlEzKM7:TR?=	MnLLV2FPT0WU
ARH-77	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLkOoxKSzVyPUCuNFczPzhizszN	NU\2[VNyW0GQR1XS
LB771-HNC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHETWM2OD1yLkC3OVQ6KM7:TR?=	MUXTRW5ITVJ?
PF-382	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXie2hKSzVyPUCuNFc2PjlizszN	MYHTRW5ITVJ?
KM12	NYrXTFNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DyXWlEPTB;MD6wO\|Y1KM7:TR?=	M2e4SnNCVkeHUh?=
HAL-01	NHrV[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXKzPJJVUUN3ME2wMlA4PjV6IN88US=>	NXLse2ZlW0GQR1XS
RPMI-8402	NYjp[W5vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;jPYVKSzVyPUCuNFc4QDlizszN	NU[weWtmW0GQR1XS
OMC-1	NY\GV3NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf1TWM2OD1yLkC3PFA1KM7:TR?=	MVrTRW5ITVJ?
HT	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nOc2lEPTB;MD6wPEDPxE1?	NVXsWoVOW0GQR1XS
QIMR-WIL	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEP3e4RKSzVyPUCuNFgxPTVizszN	NHzZT4VUSU6JRWK=
KNS-42	M3vybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTNOZhKSzVyPUCuNFgzODNizszN	MVPTRW5ITVJ?
BC-3	NWrBTWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PvW2lEPTB;MD6wPFIxPCEQvF2=	NIL2ZVlUSU6JRWK=
ES4	NWnBbpNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LlPGlEPTB;MD6wPFI6PiEQvF2=	M{jDV3NCVkeHUh?=
NCI-H23	NEC0eZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[xSYZrUUN3ME2wMlA5PDRizszN	M{LTOHNCVkeHUh?=
LB2518-MEL	NGK2bmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HwSGlEPTB;MD6wPFY6PiEQvF2=	NWP4XJNDW0GQR1XS
LC4-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvtR\|BPUUN3ME2wMlA5PzN6IN88US=>	MV;TRW5ITVJ?
SIG-M5	M3TlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMEi5NFQh\|ryP	MUXTRW5ITVJ?
LP-1	NY[yfY5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVz5bGhNUUN3ME2wMlA5QTN6IN88US=>	MXvTRW5ITVJ?
TE-8	M2j0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HjemlEPTB;MD6wPVAyPiEQvF2=	MYjTRW5ITVJ?
K-562	NWGwRllLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfYNpJiUUN3ME2wMlA6OTJizszN	M3zwfnNCVkeHUh?=
J-RT3-T3-5	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXGXGtKSzVyPUCuNFkyPTNizszN	NU\TcGdSW0GQR1XS
DU-4475	MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInoVpdKSzVyPUCuNFkyPjVizszN	NW\yZ3h4W0GQR1XS
RXF393	NInIUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHmSZljUUN3ME2wMlA6PDZ{IN88US=>	MlyxV2FPT0WU
NB5	NELtVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMEm2NlUh\|ryP	M17JT3NCVkeHUh?=
A704	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlW2TWM2OD1yLkC5O\|QyKM7:TR?=	M{jwZnNCVkeHUh?=
SF268	M2r0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMEm4NlUh\|ryP	MnWwV2FPT0WU
UACC-257	NYPReZh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMEm4N\|Mh\|ryP	NFTSXHhUSU6JRWK=
L-428	NWjKTVBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\3eVlKSzVyPUCuNVA{OiEQvF2=	NEPTeFZUSU6JRWK=
ST486	Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTDNGg3UUN3ME2wMlExPjB4IN88US=>	NHz4VHZUSU6JRWK=
SK-MM-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTTTWM2OD1yLkGwO\|A6KM7:TR?=	NF7HdnBUSU6JRWK=
COR-L279	NHe1fXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXtRldKSzVyPUCuNVA5OzJizszN	NIThbIlUSU6JRWK=
JiyoyeP-2003	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMUC4OFMh\|ryP	NWTLXIdlW0GQR1XS
GT3TKB	M17UUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorZTWM2OD1yLkGwPVE5KM7:TR?=	M4HFO3NCVkeHUh?=
HCE-T	NYTjfo5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHj2bmxKSzVyPUCuNVA6PCEQvF2=	NWHhb\|BFW0GQR1XS
SBC-1	NVjtR\|RuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\kRVJKSzVyPUCuNVEyOTlizszN	MlPmV2FPT0WU
KNS-81-FD	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTFeIJkUUN3ME2wMlEyOjd\|IN88US=>	MY\TRW5ITVJ?
NCI-H2126	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\yO2tKSzVyPUCuNVE{QTRizszN	MWDTRW5ITVJ?
EM-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELK[2RKSzVyPUCuNVE2OjlizszN	Mk\mV2FPT0WU
JAR	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMUG1PVgh\|ryP	M2X3cXNCVkeHUh?=
NB17	M1fsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwMUG2OVIh\|ryP	M{X4WXNCVkeHUh?=
LB647-SCLC	NG\JZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTFOXlKSzVyPUCuNVE4ODVizszN	NGXJfJVUSU6JRWK=
CAL-148	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\3OJVKSzVyPUCuNVE5KM7:TR?=	M{e3ZnNCVkeHUh?=
K052	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMUG4OVEh\|ryP	NULFbXRmW0GQR1XS
KARPAS-299	NEDCW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoG5TWM2OD1yLkGyNlM{KM7:TR?=	NHLJfJNUSU6JRWK=
KARPAS-422	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\EdnFKSzVyPUCuNVI1OzJizszN	MWTTRW5ITVJ?
LOXIMVI	MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMUK1NVUh\|ryP	NGTEZZJUSU6JRWK=
SCC-3	NGTqd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjFb4NjUUN3ME2wMlEzQDVzIN88US=>	Mn24V2FPT0WU
LU-139	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMUK5O\|Uh\|ryP	NXHxb2RLW0GQR1XS
COLO-320-HSR	NGXFd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HzUmlEPTB;MD6xN\|A5PiEQvF2=	MV7TRW5ITVJ?
ONS-76	M4i1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMUOxN{DPxE1?	MkjZV2FPT0WU
U-266	M2rLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:wTGlEPTB;MD6xN\|I1PSEQvF2=	MVHTRW5ITVJ?
HH	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF63bpZKSzVyPUCuNVM2OzVizszN	NV;CSnNwW0GQR1XS
BB49-HNC	NVfjOWJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkX3TWM2OD1yLkGzOVg4KM7:TR?=	Mmi3V2FPT0WU
NCI-SNU-5	M1PXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPGTWM2OD1yLkGzOVk3KM7:TR?=	NEnqO2VUSU6JRWK=
C2BBe1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3ETWM2OD1yLkGzO\|Q3KM7:TR?=	MVfTRW5ITVJ?
ML-2	NGrVeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMUO5OVMh\|ryP	NH7je4xUSU6JRWK=
SCH	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7GUWtKSzVyPUCuNVM6PzRizszN	Moe5V2FPT0WU
NCI-H82	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPj[5djUUN3ME2wMlE1OTB2IN88US=>	MVPTRW5ITVJ?
MDA-MB-134-VI	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMUSyOVIh\|ryP	NWPzbnBPW0GQR1XS
SK-N-DZ	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHDV\|RKSzVyPUCuNVQ4OTlizszN	NILGWFNUSU6JRWK=
HL-60	M4nqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjLTWM2OD1yLkG0PVIh\|ryP	NYP3UJNUW0GQR1XS
LB373-MEL-D	M4DKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMUW1N\|kh\|ryP	M1XodXNCVkeHUh?=
LB831-BLC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlf2TWM2OD1yLkG2NFc3KM7:TR?=	M1W3[3NCVkeHUh?=
SK-NEP-1	NV6zXXV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\nTWM2OD1yLkG2NVAyKM7:TR?=	NY\VS5pGW0GQR1XS
IMR-5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDETWM2OD1yLkG2OFg{KM7:TR?=	NEC2OVBUSU6JRWK=
Calu-6	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIT3[4lKSzVyPUCuNVY2OzdizszN	M3T4ZnNCVkeHUh?=
NCI-H1882	NHvaOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv6WIxKSzVyPUCuNVY4OjhizszN	MVPTRW5ITVJ?
NCI-H446	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPRPGNKSzVyPUCuNVY5QTFizszN	NWfGO4lIW0GQR1XS
GI-ME-N	Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzaTWM2OD1yLkG4NFIh\|ryP	MWjTRW5ITVJ?
MPP-89	NGHKbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PGWmlEPTB;MD6xPFEzOSEQvF2=	NGPYOnBUSU6JRWK=
CGTH-W-1	NGPG[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXuToNPUUN3ME2wMlE5PDN4IN88US=>	NYDvUINSW0GQR1XS
MEG-01	M{TJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7qZXVRUUN3ME2wMlE5PjJ6IN88US=>	NWPGRotJW0GQR1XS
NCI-H748	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;0RmFKSzVyPUCuNVg6OTFizszN	MkS5V2FPT0WU
COLO-829	NFLpUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfydYxWUUN3ME2wMlIxPjd\|IN88US=>	MmPXV2FPT0WU
GOTO	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vnSmlEPTB;MD6yNFc{KM7:TR?=	MmHxV2FPT0WU
EW-3	NWH3Vo5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMkG3NVgh\|ryP	NGTUXWNUSU6JRWK=
KY821	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvDPGpKSzVyPUCuNlIxPDVizszN	MkX2V2FPT0WU
CTB-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rSSWlEPTB;MD6yNlIzQCEQvF2=	Mlz1V2FPT0WU
TALL-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfSTWM2OD1yLkKyPVIyKM7:TR?=	MnO0V2FPT0WU
NCI-H209	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\5V\|VoUUN3ME2wMlIzQTZ{IN88US=>	NYXQSlEyW0GQR1XS
IST-MES1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrtTopoUUN3ME2wMlI{PTFizszN	Mlj3V2FPT0WU
DMS-114	NXzaWHhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzWTWM2OD1yLkKzPVk{KM7:TR?=	NUH4VoxiW0GQR1XS
SNU-C2B	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL4OWxKSzVyPUCuNlQ{OTZizszN	NIfpUFFUSU6JRWK=
DG-75	M{jWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFT6WXdKSzVyPUCuNlYyQTVizszN	MVvTRW5ITVJ?
D-336MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFziVI1KSzVyPUCuNlY2PTdizszN	MW\TRW5ITVJ?
KMOE-2	NGrTVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmG4TWM2OD1yLkK3OVM5KM7:TR?=	M1TseHNCVkeHUh?=
NB1	M1f3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmW2TWM2OD1yLkK3PVI3KM7:TR?=	NYi4Z2hDW0GQR1XS
RH-1	NH2yZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMke5PFkh\|ryP	NX;WVIZtW0GQR1XS
TE-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMki0O\|kh\|ryP	MV3TRW5ITVJ?
RPMI-6666	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jRRWlEPTB;MD6yPFg1KM7:TR?=	MoTNV2FPT0WU
TE-9	M2W0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DLd2lEPTB;MD6yPFk5PSEQvF2=	MXvTRW5ITVJ?
BT-474	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnYTWM2OD1yLkK5N\|M1KM7:TR?=	M1rOdHNCVkeHUh?=
COLO-668	NEC2ZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrJeFdKSzVyPUCuNlk1OjlizszN	MX;TRW5ITVJ?
NCI-H1581	NWjFW3J7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPCPXdKSzVyPUCuNlk3QDlizszN	M4DIZ3NCVkeHUh?=
MN-60	NUPEPIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnxTm1KUUN3ME2wMlI6QTB3IN88US=>	NVu0O5BRW0GQR1XS
L-540	M1ziUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mle0TWM2OD1yLkOwNFgyKM7:TR?=	NVuxc\|h6W0GQR1XS
MOLT-13	NYXYenlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwM{CxPFMh\|ryP	MWrTRW5ITVJ?
NCI-SNU-16	MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTGbWhKSzVyPUCuN\|AzODVizszN	M1zlWHNCVkeHUh?=
NCI-H64	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHqxenhKSzVyPUCuN\|A{OzFizszN	M1j0W3NCVkeHUh?=
CP66-MEL	M{j5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;0TWM2OD1yLkOxOFE2KM7:TR?=	M3nsR3NCVkeHUh?=
NB69	NW\XdoNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fIXmlEPTB;MD6zNlE5QCEQvF2=	NETrbJJUSU6JRWK=
NCI-H2196	NGPie\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwM{OwN\|Yh\|ryP	M1K0Z3NCVkeHUh?=
MHH-CALL-2	M4[1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwM{O0Olgh\|ryP	M4jWV3NCVkeHUh?=
HCC2157	M3K0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjJUnVKSzVyPUCuN\|M6PTRizszN	M1PyUXNCVkeHUh?=
LS-1034	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVu0O3dCUUN3ME2wMlM3Ozh6IN88US=>	MoroV2FPT0WU
BOKU	M3\kUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITHSplKSzVyPUCuN\|cyQTlizszN	NF32d4ZUSU6JRWK=
GDM-1	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjxZoVKSzVyPUCuN\|czOzRizszN	MUTTRW5ITVJ?
TGW	M{DNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rBeWlEPTB;MD6zO\|Q2OyEQvF2=	MmfyV2FPT0WU
SNU-C1	NGrqSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTrfI9TUUN3ME2wMlM5OjF3IN88US=>	NIj3PI9USU6JRWK=
LS-513	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLVfJJKSzVyPUCuN\|kxPzFizszN	NULvOG9OW0GQR1XS
NOMO-1	MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfxflBFUUN3ME2wMlM6QTdzIN88US=>	MoDuV2FPT0WU
MS-1	NH3EUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LlSGlEPTB;MD60NFE4PyEQvF2=	NV\DOHVCW0GQR1XS
EKVX	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfwN\|VKSzVyPUCuOFQ1PjFizszN	NWjNfYE{W0GQR1XS
SK-MEL-2	M2\4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrGRpdvUUN3ME2wMlQ3PCEQvF2=	M{XrS3NCVkeHUh?=
HCC1187	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPkZ5VjUUN3ME2wMlQ3PzZ6IN88US=>	NIizR2FUSU6JRWK=
HCC2218	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzhTWM2OD1yLkS3NlI4KM7:TR?=	M{PHcXNCVkeHUh?=
NCI-H187	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljTTWM2OD1yLkS3PFQh\|ryP	MWrTRW5ITVJ?
DB	NYDhVIxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnJUplKSzVyPUCuOVAxPTVizszN	NUHqcHZYW0GQR1XS
NCI-H69	NGfLfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwNUCyOFch\|ryP	NUfmNWZNW0GQR1XS
NCI-H1694	NID2TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwNUC2PVch\|ryP	MWjTRW5ITVJ?
CA46	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwNUC5NVch\|ryP	NH\hO4hUSU6JRWK=
EHEB	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwNUGxPVMh\|ryP	Ml7uV2FPT0WU
NCCIT	MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrMdo4yUUN3ME2wMlU1OzJzIN88US=>	M{jLcHNCVkeHUh?=
NCI-H720	NUS2TXZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXuSIhKSzVyPUCuOVQ6PjJizszN	NU\Ed3VmW0GQR1XS
LU-134-A	NFXmTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmC5TWM2OD1yLkW1Nlk3KM7:TR?=	MmD3V2FPT0WU
MC-CAR	MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzmN3lSUUN3ME2wMlU2PDNzIN88US=>	M3;ibHNCVkeHUh?=
NEC8	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fzTmlEPTB;MD61OlE4OiEQvF2=	MorPV2FPT0WU
NCI-H524	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnWOlBKSzVyPUCuOVg4PDhizszN	NUfEN5JqW0GQR1XS
NCI-H1963	NHW0V2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVX2UnlmUUN3ME2wMlYzPThizszN	NYj0TII3W0GQR1XS
SU-DHL-1	NH;nVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXoTWM2OD1yLk[0OVI3KM7:TR?=	NWPTNY5qW0GQR1XS
NCI-H1522	NXe2VmJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3lTWM2OD1yLk[0PFg{KM7:TR?=	M1vkbnNCVkeHUh?=
NCI-H1155	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHzXm9KSzVyPUCuOlU{PSEQvF2=	MV;TRW5ITVJ?
D-263MG	NHjnNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoD0TWM2OD1yLk[2NVAyKM7:TR?=	M4TOZXNCVkeHUh?=
TE-6	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHzbHJlUUN3ME2wMlY5OTB2IN88US=>	MXzTRW5ITVJ?
NCI-H1417	NUe2XG5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLqPFdzUUN3ME2wMlY6PzFzIN88US=>	M4TqOnNCVkeHUh?=
NCI-H510A	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwN{eyN\|Yh\|ryP	MmDnV2FPT0WU
KARPAS-45	NXfLWXlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrvc2ZtUUN3ME2wMlc5OjN3IN88US=>	M3;jZXNCVkeHUh?=
IST-SL1	Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFroZppKSzVyPUCuPFU5OjVizszN	MmDGV2FPT0WU
COLO-824	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1K1VGlEPTB;MD64O\|g{PSEQvF2=	MlPLV2FPT0WU
NCI-H526	MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwOUC5OVgh\|ryP	M1vhcHNCVkeHUh?=
NCI-H719	NWLXXokyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mne5TWM2OD1yLkm2OlU4KM7:TR?=	MXvTRW5ITVJ?
SF539	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnnXGRKSzVyPUCuPVg{QTZizszN	NFXTeplUSU6JRWK=
NKM-1	M2HCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjRTWM2OD1yLkm4OlY{KM7:TR?=	M2\DOHNCVkeHUh?=
A253	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjpV3RDUUN3ME2wMlk5QDh3IN88US=>	MXHTRW5ITVJ?
TE-441-T	NV7YNWd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDTTWM2OD1zLkC0N\|Uh\|ryP	NWPnWVFJW0GQR1XS
COR-L88	MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXq2OHpmUUN3ME2xMlEyOzV2IN88US=>	NHnZVIRUSU6JRWK=
CPC-N	NYDONo5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXtR2NpUUN3ME2xMlE2QDh6IN88US=>	M3OwNHNCVkeHUh?=
NCI-H2107	NFW1SXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Lh[WlEPTB;MT6xO\|I3OSEQvF2=	M4TXSXNCVkeHUh?=
ECC4	M2T4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[5TWM2OD1zLkG4Olk{KM7:TR?=	MV;TRW5ITVJ?
NCI-H2141	M{Ltc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTFwMUmyPVkh\|ryP	NF61TmVUSU6JRWK=
NCI-H1770	M3H2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLXTWM2OD1zLkOyPVI5KM7:TR?=	NGC5bGtUSU6JRWK=
NCI-SNU-1	NVXsT2VHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInEdXFKSzVyPUGuN\|MxPCEQvF2=	MlflV2FPT0WU
LU-165	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTFwNEW0Olch\|ryP	NVm3TG05W0GQR1XS
Raji	M1\JVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoO0TWM2OD1zLkS3NlU6KM7:TR?=	MWnTRW5ITVJ?
EW-24	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnOOpRWUUN3ME2xMlU1PjF7IN88US=>	MX7TRW5ITVJ?
KP-N-RT-BM-1	MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjLfGdDUUN3ME2xMlU3PTVzIN88US=>	MVfTRW5ITVJ?
SK-MEL-1	NHjLSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vkNGlEPTB;MT62OFg4PyEQvF2=	M2jtXXNCVkeHUh?=
SCLC-21H	NF62[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvNTWM2OD1zLk[2OlUyKM7:TR?=	Ml;tV2FPT0WU
SIMA	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHMfIhKSzVyPUGuOlgzOzNizszN	M4f3fnNCVkeHUh?=
NCI-H1304	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInIUIpKSzVyPUGuO\|A4PjVizszN	MYDTRW5ITVJ?
REH	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHmVGRDUUN3ME2xMlcyODd6IN88US=>	NX\CTVV7W0GQR1XS
KP-N-YS	NXfKepZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjJWGdKSzVyPUGuPVM2PTFizszN	MoHhV2FPT0WU
DMS-153	NGC2fIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTFwOUe1PUDPxE1?	M2fhOXNCVkeHUh?=
NB10	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fmbGlEPTB;Mj6yNFg4QCEQvF2=	Mne2V2FPT0WU
NCI-H345	MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvFZXVKSzVyPUKuOlE6ODVizszN	MY\TRW5ITVJ?
SK-N-FI	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jEWWlEPTB;Mj63OVM5OSEQvF2=	NVfiTIZDW0GQR1XS
NCI-H1092	NV3qNI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr1T2NvUUN3ME2yMlk2Ozl2IN88US=>	MkfiV2FPT0WU
KM-H2	NVX6eow3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfTNnhKSzVyPUOuOlU{QTZizszN	M2fKWXNCVkeHUh?=
KG-1	MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTNwN{G2PFgh\|ryP	NELud2FUSU6JRWK=
D-283MED	NV;yNHZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIWzTIZKSzVyPUOuO\|U5PyEQvF2=	M4HZT3NCVkeHUh?=
LU-65	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWW0RZpMUUN3ME20MlEyPDh3IN88US=>	NIH5RmVUSU6JRWK=
MSTO-211H	MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG5TWM2OD12LkG4PFk5KM7:TR?=	M3\tZnNCVkeHUh?=
NCI-H2081	NEi5blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{ezSWlEPTB;ND6yPVE4PCEQvF2=	M1zrSnNCVkeHUh?=
D-247MG	MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPpTZdKSzVyPUSuOFMyQTFizszN	M{e4[HNCVkeHUh?=
P31-FUJ	M2OzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDkPJdPUUN3ME20MlQ2ODF7IN88US=>	NFjtVpVUSU6JRWK=
DMS-79	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTRwOUOxPFMh\|ryP	MkLBV2FPT0WU
KASUMI-1	M4nTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\TbFFXUUN3ME20Mlk4PTB7IN88US=>	NFfLXo5USU6JRWK=
JVM-3	NF\uWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DORmlEPTB;NT6yOVAyPCEQvF2=	NFPkNWpUSU6JRWK=
LAN-6	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1u0TmlEPTB;NT61NVc{PiEQvF2=	M4LsZ3NCVkeHUh?=
DJM-1	M3\GW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLldI1KSzVyPUWuOVYxOjlizszN	M2faOXNCVkeHUh?=
JVM-2	M3\1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTVwNkewPVIh\|ryP	NHHw[ZZUSU6JRWK=
U-87-MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDNfYRQUUN3ME21Mlg6QTZ2IN88US=>	MXnTRW5ITVJ?
SHP-77	M2jzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPUTodyUUN3ME21Mlk1QTJ6IN88US=>	MlLzV2FPT0WU
RPMI-8866	NUHxXIlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTZwMkewNVMh\|ryP	NF31UmlUSU6JRWK=
ES7	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX72RmpHUUN3ME22MlM6QTJ2IN88US=>	NG\DNVJUSU6JRWK=
WSU-NHL	NVTtSG9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1:2cGlEPTB;Nj61NVYxQSEQvF2=	MV3TRW5ITVJ?
CAS-1	M3jGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTFTWM2OD15LkC5O\|Q6KM7:TR?=	M{Pp[3NCVkeHUh?=
MHH-NB-11	NFTBV\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fmNWlEPTB;OD6yN\|E2OiEQvF2=	M{fZbXNCVkeHUh?=
ES5	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEflSmJKSzVyPUmuOVIzQDZizszN	NELMSXNUSU6JRWK=
HDLM-2	MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHROodKSzVyPUmuPVU6ODJizszN	M1HJ[nNCVkeHUh?=
NCI-H2171	NEOxRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PXUmlEPTB;MUCuOVkzPyEQvF2=	NICyWVRUSU6JRWK=
LNCaP-Clone-FGC	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYO0NXlIUUN3ME2xNU4{PzF6IN88US=>	MnjzV2FPT0WU
NCI-H1395	M{PvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTF{LkK2PVkh\|ryP	MXLTRW5ITVJ?
NCI-H1436	M1TlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHmNmFKSzVyPUGzMlMyQTVizszN	NF72eZBUSU6JRWK=
RCC10RGB	M{PCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorCTWM2OD1zMz6zNlIyKM7:TR?=	M4DtZnNCVkeHUh?=
SW684	NVHtT495T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXkUG1iUUN3ME2xN{46Pzl5IN88US=>	NVH6NGsxW0GQR1XS
NCI-H1650	NGrTflNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mme1TWM2OD1zNT6wOFQ4KM7:TR?=	MorRV2FPT0WU
EW-13	M2TWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn1U2VKSzVyPUG1MlIxOjFizszN	NXSyfWJiW0GQR1XS
EC-GI-10	NXf3SFZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWX0XJRNUUN3ME2xOU45PjR2IN88US=>	MoiyV2FPT0WU
CHP-126	NHnxbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2q0R2lEPTB;MUeuNVkyQCEQvF2=	NYfyZml1W0GQR1XS
NCI-H226	M1zFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXKzTHd4UUN3ME2xPE4xPDB\|IN88US=>	NILRWpdUSU6JRWK=
NCI-H1838	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHwN3lsUUN3ME2yNE4yQDR6IN88US=>	NYrZc5JQW0GQR1XS
EW-11	NGrwWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2f4d2lEPTB;MkSuNlcyQCEQvF2=	MYjTRW5ITVJ?
EB2	M{HQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\iRWlEPTB;M{GuOVMyQCEQvF2=	NGDmOpRUSU6JRWK=
D-502MG	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULKelFYUUN3ME20N{46OjJ7IN88US=>	M1zERnNCVkeHUh?=
U-698-M	M3\Rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXQXXk1UUN3ME20PE45PjdzIN88US=>	NYPFNFJbW0GQR1XS
ES3	M{D2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2KxTWlEPTB;NEmuN\|g6OyEQvF2=	MULTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ATF4 / p-S6K(T389) / S6K / p-eIF2α(S51) / eIF2α / 4EBP1 / eIF3b; PubMed: 28494858 Cell Rep 4E-BPs are required for mTOR control of ATF4. 4E-BP1/2 wild-type (WT), double knockout (DKO), or DKO MEFs stably expressing 4ebp1 (DKO + 4ebp1) were treated with vehicle (DMSO) or 250 nM Torin 1 for 4 hr. Cell extracts were analyzed by immunoblotting for the indicated proteins. LC3 / p62 / PARP / pAKT(S473) / p4EBP1(S65) / pS6K1(T389) / pS6(S235/236); PubMed: 24126619 Int J Oncol Cells were treated with increasing doses of the mTOR inhibitors, torin 1 (A) and rapamycin (B), in RPMI-1640 containing 10% FBS for 2 days. LC3 processing, p62 accumulation, PARP cleavage, AKT phosphorylation and mTOR pathway activity (indicated by phosphorylation of 4E-BP, S6K1 and S6) were analyzed by western blotting of total cell lysates. GAPDH was the control for protein loading. p-mTOR(S2481) / mTOR / rictor / Sin1 / p-Akt S473 / p-Akt T450 / p-Akt T308 / p-S6K1 T389 / S6K1; PubMed: 21965657 J Biol Chem mTOR kinase activity controls abundance of SIN1. MDA-MB-435 cells were incubated with specific mTOR inhibitor (0.5 μm TORIN) for 24 or 48 h and analyzed. Vinculin / p-S6; PubMed: 28757207 Mol Cell A375 cells were treated with Torin1 for 48 h and localization of proteins was visualized by confocal microscopy. Scale bar, 50 μm. Focal adhesion size was measured by Fiji program.	28494858 24126619 21965657 28757207
Immunofluorescence	lipin-1; PubMed: 28347999 FASEB J Inhibition of mTOR activity promoted the nuclear translocation of lipin-1. After treatment with or without torin 1 for 4 h, cells expressing HA-lipin-1 were fixed and stained with a rabbit HA antibody followed by Alexa 594–conjugated goat anti-rabbit secondary antibody. Nuclei were stained with DAPI. Scale bars, 20 μM.	28347999
Growth inhibition assay	Cell viability; PubMed: 28757207 Mol Cell Cancer cell lines were grown in complete media with/without mTOR inhibitor, Torin1 (250 nM). Media and Torin1 were replaced every 2 days and cells were counted at the indicated time points. Data are the means ± SD of three separate experiments performed in triplicate.	28757207

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	- Collapse Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: U87MG xenograft model Formulation: Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

- Collapse

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1

Cited by 98 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Torin 1 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1

Cited by 98 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Torin 1 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)